Communiqués Lipum AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 16:45:38 07/06/2024			Varia. 5j.	Varia. 1 janv.
7,6 ^SEK	+4,83 %		+10,95 %	+16,56 %

28/05	Lipum AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
06/05	Lipum obtient un prêt de 20 millions de couronnes suédoises de Flerie Invest	MT

Lipum: A new approach to chronic inflammation	29/05	AQ
Lipum Q1 - Initiating preparations for phase II	28/05	AQ
Lipum AB – interim report Q1 for the period January-March 2024	28/05	AQ
BioStock: Flerie Invest continues to support Lipum	13/05	AQ
Lipum receives loan commitment of SEK 20 million	06/05	AQ
BioStock: Lipum's CEO looks ahead after the rights issue	26/04	AQ
Lipum announces final outcome of the rights issue	25/04	AQ
Lipum - Financed and ready to go	24/04	AQ
Lipum announces preliminary outcome of the rights issue	23/04	AQ
Lipum and NorthX Biologics enter into new strategic manufacturing alliance	18/04	AQ
Lipum has been granted funding from Swelife	12/04	AQ
Lipum publishes supplement to the prospectus regarding the rights issue	05/04	AQ
Lipum publishes prospectus regarding the rights issue	03/04	AQ
BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment	03/04	AQ
Lipum AB - Report from the Extraordinary General Meeting	02/04	AQ
Lipum strengthens its protection of the drug candidate SOL-116 through a patent application for inflammation-driven cancer	02/04	AQ
BioStock: Lipum has included first RA patient	22/03	AQ
Statement from the Board of Directors of Lipum regarding the mandatory public offer from Flerie Invest AB	20/03	AQ
LIPUM REPORTS FIRST PATIENT INCLUDED IN THE ONGOING PHASE I CLINICAL STUDY WITH SOL-116	19/03	AQ
BioStock: Lipum advances to phase II with capital raise, moves production to Sweden	12/03	AQ

Aucun résultat pour cette recherche